Please click on the icons below to learn more about the portfolio of companies held by the B Ordinary Shares (SENECA GROWTH CAPITAL VCT PLC B ORD 1P).
B Share Class Portfolio
Current Portfolio
+ Click for info
Abingdon Health
- Click to close
Abingdon Health
Abingdon Health (AIM: ABDX) is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.
The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world.
To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader. The Company has developed and is manufacturing the AbC-19 Rapid Test, an antibody test for COVID-19 indicating whether a person is generating IgG antibodies to the spike protein of the SARS-CoV-2 virus. The same IgG antibodies that are present following infection or vaccination.
+ Click for info
Alderley Lighthouse Labs
- Click to close
Alderley Lighthouse Labs
Alderley Lighthouse Labs was founded by Mark Wigglesworth and Simon Chapman who were previously given responsibility during Covid-19 for establishing the emergency ‘Lighthouse’ capability at Alderley Park; a ‘super-lab’ created from scratch that grew to accommodate over 750 staff members and 100,000 tests a day, with the team drawing widespread praise and recognition for their role in establishing the largest diagnostics network in UK history.
The company supports both public and private customers in the UK from its full service diagnostic facility in Alderley Park. With an initial focus on blood science and molecular diagnostics, an expanded service offering will include histology and next generation sequencing (oncology).
+ Click for info
Aptamer
- Click to close
Aptamer
Aptamer is a leader in the provision of aptamer discovery services and the development of aptamer-based reagents. The Group solves intractable problems for biotech and big pharma by developing molecular binders called aptamers, as an alternative to antibodies which fail to perform 50% – 60% of the time. Led by an experienced team, Aptamer has developed novel, proprietary aptamer technology, known as Optimer® binders, which offer further performance and commercial benefits in addition to those of standard aptamers.
Aptamer operates across three life science sectors: custom services (research and bioprocessing tools), diagnostics and therapeutics. The Group has an existing blue-chip customer base and has supplied or collaborated with 75% of the global top 20 pharmaceutical companies.
Aptamers are a disruptive technology and next generation affinity ligand in the well-established global antibody market. The aptamer market is set to expand rapidly over the next five to 10 years into a multi-billion-dollar world-wide market and is forecast to grow at 18-28% per annum.
+ Click for info
Arecor Ltd
- Click to close
Arecor Ltd
Arecor was a spin-out from Insense (qv) to commercialise technology developed by Insense for enabling biologics to maintain their integrity without the need for refrigeration – this both reduces cost and also helps deployment in developing countries where temperature monitored cold storage facilities are in short supply. The technology also assists in maintaining the integrity and function of proteins exposed to ionizing radiation as the means of sterilisation.
+ Click for info
Bidstack Group plc
- Click to close
Bidstack Group plc
Bidstack is an advertising technology company which provides dynamic, targeted and automated native in-game advertising for the global video games industry across multiple platforms. Its proprietary technology is capable of inserting advertisements within video games. Bidstack’s customers are games publishers and developers (on the supply side), and advertising agencies, brands and media-buying platforms (on the demand side).
+ Click for info
Bright Network
- Click to close
Bright Network
Bright Network is a media technology platform which enables blue-chip employers to reach, identify and recruit high-quality graduates and young professionals. London-based Bright Network is led by serial entrepreneur James Uffindell, who previously established, grew, and successfully exited from another business in the education sector. The business is chaired by Zach Miles, who was the founder and latterly CEO of Vedior, a multinational recruitment company, which was acquired by Randstad for €3.3 billion.
Its platform uses advanced data analytics and cutting-edge technology to pre-screen candidates and ensure that its membership contains only the top 20% of graduate talent. The quality of Bright Network’s membership helps drives efficiencies in the recruitment process and improved candidate shortlisting outcomes for employers. As a result, the business has established a strong client base of over 250 employers, which includes global blue-chip organisations such as Bloomberg, Deloitte, Goldman Sachs, Morgan Stanley, PwC, P&G SkyScanner and Vodafone.
+ Click for info
Celadon Pharmaceuticals Plc
- Click to close
Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company targeting the research, cultivation, manufacturing and supply of cannabinoid-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabinoid-based medicines for other conditions such as autism. Its UK facility comprises a laboratory designed to meet UK-GMP standards, and capacity for a large indoor hydroponic growing facility that has received a Home Office Licence to legally grow high THC medicinal cannabis for the purpose of producing test batches of cannabis oil to support its application to the MHRA. The Company’s subsidiary, LVL, owns a MHRA conditionally approved cannabis trial using cannabis based medicinal products to treat chronic pain in the UK.
+ Click for info
Engage XR Holdings plc
- Click to close
Engage XR Holdings plc
ENGAGE XR Holdings plc is metaverse technology company focused on becoming a leading global provider of virtual communications solutions through its new fully featured corporate metaverse, ENGAGE Link.
The Company also has a proprietary software platform, ENGAGE, which provides users with a platform for creating, sharing, and delivering VR content for education, training, and online events through its three solutions: Virtual Campus, Virtual Office, and Virtual Events.
+ Click for info
Evgen Pharma
- Click to close
Evgen Pharma
Evgen is based in Liverpool, at the Liverpool Science Park and was founded in 2007 by Dr Stephen Franklin.
Evgen is a clinical stage drug development company whose lead programmes are in cancer and subarachnoid haemorrhage (a type of stroke). It is also carrying out preclinical work in relapsing remitting multiple sclerosis.
Evgen’s core technology is Sulforadex®, a novel, synthetic and stabilised version of the naturally occurring compound sulforaphane. Sulforaphane is an established anti-cancer agent that benefits from a huge amount of peer-reviewed scientific literature identifying both its anti-cancer and neuroprotective characteristics. However, its commercial development as a potential prescription medicine has been prevented by the instability of the compound. Evgen’s Sulforadex® technology overcomes this problem by creating a stable version of sulforaphane, which can be delivered as a tablet or capsule.
The potential of Sulforadex® has allowed Evgen to attract a highly experienced commercial, scientific and advisory team. The company is led by Chief Executive Dr Stephen Franklin, who has a track record in the commercialisation of intellectual property, and Chairman Barry Clare, the former director of the Boots Company plc and head of its Boots Healthcare International business.
+ Click for info
Fabacus
- Click to close
Fabacus
Fabacus is an independent software company that has developed a complete product lifecycle solution: Xelacore, aimed at bringing transparency to supply chain networks, with an initial focus on resolving the interaction and information flow between global licensors and their licensees.
Currently, there is a fundamentally flawed data capture process between licensors and licensees; and a disconnection from the framework of retail standards that have underpinned and continue to enable the retail value chain. This has resulted in an inability to correctly address known shortcomings in respect to data management and hinder the needed digital transformation of licensors in the digitally evolving retail landscape.
Fabacus’s solution, Xelacore, is a modular, Software as a Service solution with an intuitive interface and proprietary data aggregation and management engine that allows all stakeholders to operate on a single unified and collaborative platform. It bridges the gaps in an inefficient process within the current retail ecosystem by creating authenticated, enriched universal records that unlock opportunities, reduce risk and drive performance for both licensors and licensees.
+ Click for info
Gelion plc
- Click to close
Gelion plc
Gelion was founded as a spin-out from the University of Sydney in 2015 by Professor Thomas Maschmeyer, one of the world’s leading chemists who was awarded the Australian Prime Minister’s Prize for Innovation 2020.
Gelion is a global renewable-energy storage innovator. By designing leading-edge battery technology for stationary and mobile energy, the Company supports the transition to a sustainable economy while delivering value for customers and investors.
The Gelion Endure battery uses low-cost, abundant raw materials and is based on a chemistry that is highly resistant to fire.
With applications in agriculture, mining, water management and irrigation the battery is highly adaptable for off-grid use.
The batteries are also scalable, using lead-acid battery manufacturing technology, and the Company expects to develop megawatt-hour capacity for large-scale infrastructure, including for solar and wind farms.
In addition to investing in the growth of its zinc-bromide technology, the Company will use funding to develop its mobile energy division to enhance existing lithium-ion and lithium-sulphur battery technologies used in electric vehicles and the emerging market in electric aviation.
For the mobile market, Gelion’s technology pipeline includes:
Highly tuneable, low-cost silicon nanoparticle additives for next-generation advanced lithium-ion batteries, which are safer and have higher energy density.
A low-cost additive, which increases the lifetime of lithium-sulphur batteries by more than four times, delivering up to three times higher energy by weight than conventional lithium-ion batteries.
Using additive technology developed by its R&D team, which cooperates closely with scientists at the School of Chemistry and the University of Sydney Nano Institute, Gelion will develop and license additives for advanced lithium-silicon and lithium-sulphur technologies for ultra-high-density batteries to extend the cycle-life and safety of mobile energy storage.
+ Click for info
Geomiq
- Click to close
Geomiq
Geomiq was founded in London in 2017, with the goal of transforming and streamlining the manufacturing industry. Since then, it has become the digital manufacturing platform of choice for over 1200+ professional engineers and procurement teams from over 500 fast-moving hardware companies, and has partnered with over 220 exceptional suppliers in over 16 countries. The company keeps innovation, constant learning and exceptional customer support at the heart of what it does, and the team is building a world where affordable yet world-class innovation is available to all from a single access point.
Geomiq was established to solve critical supply chain risks by leveraging technology and a machine-learning-powered matching system to connect buyers and sellers of custom manufactured parts. Essentially, Geomiq’s platform allows engineers and procurement teams to shorten product development cycles and get products to market faster by removing key points of failure that hamper so many organisations. Customers include BMW, Unilever, Brompton, Ocado, TfL and Saint-Gobain, and so far over a million manufactured parts have been generated through the platform
+ Click for info
HubBox
- Click to close
HubBox
HubBox has developed plug-and-play software that gives shoppers a choice between home delivery and local pickup when they check-out on a retailer’s website. This software has been created in conjunction with the largest global delivery network providers (including UPS and DPD) and is compatible with major ecommerce platforms like Shopify.
Couriers are facing eroding margins on home deliveries as costs associated with the ‘last mile’ problem rise, and retailers are suffering from lost deliveries and failed delivery charges. HubBox provides ecommerce software that integrates with both the retailer and the courier, enabling the retailer to offer shoppers the option to Click & Collect from the courier’s network of Pick Up Points. The software turns what would otherwise be a complex, costly and lengthy piece of custom development work for retailers into a simple integration that can be completed in a matter of hours.
Customers include Macy’s, Liberty, UGG, Hobbs, Charlotte Tilbury, Belstaff and Laithwaite’s Wine.
+ Click for info
Northcoders plc
- Click to close
Northcoders plc
Northcoders is a market leading provider of coding and software development training for businesses and individuals. Founded in 2015, its business model operates a hybrid structure with a flagship site in Manchester and other sites in Leeds, Birmingham and Newcastle supported by a proven digital offering to support its students across the UK.
Powered by IP rich technology, Northcoders’ coding school offers boot camp courses to individuals from a range of backgrounds, delivered through virtual and physical learning. The Group also works with blue chip corporates across multiple sectors to supply innovative EdTech solutions for the upskilling and reskilling of employees, and is also a registered provider of government-backed apprenticeships in the field.
With a keen focus of inclusivity, diversity and quality at its core, Northcoders aims to address the digital skills gap in the UK to meet the increasing demand for digital specialists from businesses and public agencies. It operates in a significant and growing market with structural growth trends further accelerated by Covid-19.
Northcoders was admitted to trading on AIM in July 2021.
+ Click for info
Old St Labs
- Click to close
Old St Labs
Old St Labs is a provider of cloud based, supplier collaboration tools for large, blue chip customers, enabling them to manage key supplier relationships and strategic project work. The core product, Vizibl, seeks to make supplier collaboration much more straight forward, with key focus on compliance, savings / efficiency and driving growth across the business.
Vizibl is the only SaaS workspace that supports collaborative supplier relationships, bringing all points of contact together in one place, providing visibility across the company and eliminating duplication of efforts. Vizibl’s real-time reporting speeds up decision making, drawing on and sharing the expertise of the community in the process. The offering taps into a growing trend in supplier collaboration, having moved on from the initial focus on compliance, to an increased emphasis on savings / efficiency, and recent developments highlighting the benefits in terms of wider growth strategy for large customers.
Vizibl provides the infrastructure, governance and reporting capabilities to optimise present supplier performance and acts as a springboard for those collaborative supplier relationships. The product is CRM / ERP agnostic, working alongside all major software providers to ensure the collaboration software is insightful and informative.
+ Click for info
Optibiotix Health
- Click to close
Optibiotix Health
OptiBiotix (AIM:OPTI) is developing a range of technologies, which modulate the human microbiome to prevent and manage human disease. A global market of strategic interest to pharmaceutical, food, health and wellbeing companies, the human microbiome is forecast to become one of the world’s fastest growth areas.
OptiBiotix identifies and develops microbial strains, compounds and formulations for use in food ingredients, supplements and active compounds that can impact on human physiology, deriving potential health benefits.
With an established pipeline of microbiome modulators, the OptiBiotix team works in the prevention and management of chronic lifestyle diseases including obesity, hypercholesterolemia and lipid profiles, and diabetes.
+ Click for info
Oxford Biodynamics plc
- Click to close
Oxford Biodynamics plc
Oxford BioDynamics is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology checkpoint inhibitor treatments, launched in February 2022.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.
The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases.
+ Click for info
Polarean Imaging Plc
- Click to close
Polarean Imaging Plc
Polarean Imaging plc is a healthcare technology company which has developed a state of the art proprietary drug-device combination addressing a specific global unmet need in the field of healthcare. The company’s technology has been developed over a number of years and provides a visual representation of ventilation and gas exchange in the lungs. Xenon, when polarised in Polarean’s proprietary drug-device system, permits functional, regional and quantitative imaging of the lungs using MRI, without the risk of exposing patients to ionising radiation. The technology is being used in the field of respiratory disease – both in the understanding and treatment of it.
+ Click for info
Poolbeg Pharma Plc
- Click to close
Poolbeg Pharma Plc
Poolbeg Pharma is a clinical-stage pharmaceutical company focused on the development and commercialisation of therapies to treat and prevent infectious diseases. Headquartered in London, the business is a spin out from Open Orphan Plc and the management team has proven capabilities in identifying, acquiring and accelerating assets through development to commercialisation. It has adopted a capital-light model which enables it to develop multiple products faster and more cost effectively than the traditional biotech model, and the company aspires to become a “one-stop shop” for big pharma to find Phase II ready products for development and commercialisation.
The company’s lead asset is POLB 001, a drug with the potential to treat serious unmet needs in patients suffering from severe influenza.
+ Click for info
ProBiotix Health Plc
- Click to close
ProBiotix Health Plc
ProBiotix Health develops probiotics (live microbes that, when ingested, can alter the composition of the microbiome and improve human health) to tackle cardiovascular disease and other lifestyle conditions which are affecting growing numbers of people across the world. ProBiotix Health’s cholesterol reducing probiotic, Lactobacillus plantarum ECGC13110402 (“LP-LDL®), is manufactured in pharmaceutical GMP-certified facilities and protected worldwide by in the region of 5 patent families, comprising 27 patents and pending patent applications, and 22 trademarks.
+ Click for info
SilkFred
- Click to close
SilkFred
Silkfred is an online marketplace for independent ladies’ fashion brands. The business was founded in 2011 with the aim of creating an efficient marketplace for emerging fashion designers to bring products to market and establish their brand in the sector. The business now works with c.600 independent brands, selling to over 500k customers.
Silkfred acts as a central marketing and sales platform
for these brands, charging commission in exchange for these services, and as a result the business itself takes minimal inventory / working capital risk on new brands, lines or products.
The business model revolves around a market leading and scalable customer service platform, and as such Silkfred are continually investing in core infrastructure and constantly seeking innovative methods to enhance the customer experience.
+ Click for info
SkinBioTherapeutics Plc
- Click to close
SkinBioTherapeutics Plc
SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Cath O’Neill and Professor Andrew McBain.
SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.
The aim of the Company is to develop its SkinBiotix® technology into commercially successful products supported by a strong scientific evidence base. SkinBioTherapeutics’ commercial strategy is to engage health and wellbeing and/or pharmaceutical companies in early dialogue to build up relationships and maintain communication on technical progress until one or more commercial deals can be secured.
+ Click for info
SolasCure
- Click to close
SolasCure
SolasCure aims to support healthcare professionals with wound care products that significantly improve the health and wellbeing of patients with chronic wounds. Chronic wounds impact over 40 million people worldwide, with care consuming around 10% of health care expenditure in many countries; while spending on advanced wound care products is over £5 billion each year.
These figures continue to grow as prevalence of obesity and diabetes increases. SolasCure’s first product, Aurase® is a hydrogel containing a safe, active, highly-specific enzyme, isolated and cloned from medical maggots. The medical use of Aurase® should lead to faster wound cleaning – promoting better patient outcomes and reduced healthcare costs. SolasCure was born in 2017 as a spin-off from BRAIN, a leading German biotech company, and is currently preparing a clinical study for Aurase to reach market authorisation
+ Click for info
Ten80 Group
- Click to close
Ten80 Group
The company is a SAP focussed on-demand outcome-based delivery solution.
Its aim is to connect every SAP customer with every SAP consultant globally, delivering outcome-based projects rather than time-driven costs through the contractor or freelancer marketplace.
The SAP global consultancy market is estimated to be worth in excess of £300bn.
+ Click for info
Verici Dx Plc
- Click to close
Verici Dx Plc
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.
Full and Partial Exits
+ Click for info
Abingdon Health
- Click to close
Abingdon Health
Abingdon Health (AIM: ABDX) is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.
The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world.
To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader. The Company has developed and is manufacturing the AbC-19 Rapid Test, an antibody test for COVID-19 indicating whether a person is generating IgG antibodies to the spike protein of the SARS-CoV-2 virus. The same IgG antibodies that are present following infection or vaccination.
+ Click for info
ADC Biotechnology
- Click to close
ADC Biotechnology
ADC Biotechnology is developing new process technology to help drug developers meet conjugation process challenges in the testing and production of new antibody drug conjugate (ADC)-based anti cancer drugs. The technology signals faster, simpler and less costly development for an exciting new family of drugs.
With surging numbers of “second generation” drugs in development, tumour-selective ADCs are building a significant position in the oncology field – the fastest growing sector in healthcare.
ADC Bio’s technology aims to become a new paradigm in the way ADCs are developed and manufactured, increasing accessibility for patients by helping to contain ADC production complexity and cost. The patented Lock – Release technology results in fast, simple and robust conjugation processes, with the potential to eliminate several process steps whilst enhancing product quality.
ADC Bio brings knowledge, experience and technical differentiation to the rapid growth ADC sector and is an ideal partner for basic research, development, scale-up and commercialisation challenges.
+ Click for info
Bidstack Group plc
- Click to close
Bidstack Group plc
Bidstack is an advertising technology company which provides dynamic, targeted and automated native in-game advertising for the global video games industry across multiple platforms. Its proprietary technology is capable of inserting advertisements within video games. Bidstack’s customers are games publishers and developers (on the supply side), and advertising agencies, brands and media-buying platforms (on the demand side).
+ Click for info
Clean Power Hydrogen plc
- Click to close
Clean Power Hydrogen plc
CPH2 is a rapidly-growing UK-based technology and manufacturing company which is focussed on the commercial production of “green” hydrogen in a simple, safe, and sustainable manner using its IP-protected Membrane-Free ElectrolyserTM (“MFE”) technology.
A decade of dedicated research and product development has resulted in the creation of a technology which is designed to deliver a modular solution to the hydrogen production market in a cost-effective, scalable, reliable and long-lasting way.
CPH2’s strategic objective is to deliver the lowest Levelised Cost of Hydrogen (“LCOH”) in the market in relation to the production of green hydrogen. The Group’s MFE technology is already commercially available and demonstrating cost efficiencies and technological advantages.
+ Click for info
Gelion plc
- Click to close
Gelion plc
Gelion was founded as a spin-out from the University of Sydney in 2015 by Professor Thomas Maschmeyer, one of the world’s leading chemists who was awarded the Australian Prime Minister’s Prize for Innovation 2020.
Gelion is a global renewable-energy storage innovator. By designing leading-edge battery technology for stationary and mobile energy, the Company supports the transition to a sustainable economy while delivering value for customers and investors.
The Gelion Endure battery uses low-cost, abundant raw materials and is based on a chemistry that is highly resistant to fire.
With applications in agriculture, mining, water management and irrigation the battery is highly adaptable for off-grid use.
The batteries are also scalable, using lead-acid battery manufacturing technology, and the Company expects to develop megawatt-hour capacity for large-scale infrastructure, including for solar and wind farms.
In addition to investing in the growth of its zinc-bromide technology, the Company will use funding to develop its mobile energy division to enhance existing lithium-ion and lithium-sulphur battery technologies used in electric vehicles and the emerging market in electric aviation.
For the mobile market, Gelion’s technology pipeline includes:
Highly tuneable, low-cost silicon nanoparticle additives for next-generation advanced lithium-ion batteries, which are safer and have higher energy density.
A low-cost additive, which increases the lifetime of lithium-sulphur batteries by more than four times, delivering up to three times higher energy by weight than conventional lithium-ion batteries.
Using additive technology developed by its R&D team, which cooperates closely with scientists at the School of Chemistry and the University of Sydney Nano Institute, Gelion will develop and license additives for advanced lithium-silicon and lithium-sulphur technologies for ultra-high-density batteries to extend the cycle-life and safety of mobile energy storage.
+ Click for info
genedrive plc
- Click to close
genedrive plc
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications.
genedrive is based in Manchester, United Kingdom. The business was floated on the London AIM market in 2007, trading as Epistem Holdings Inc but was renamed genedrive plc in July 2016 to reflect the new direction of the company targeting molecular diagnostic requirements at the point of need. The legacy contract research services divisions were divested in June 2018.
Read more about genedrive here
+ Click for info
Optibiotix Health
- Click to close
Optibiotix Health
OptiBiotix (AIM:OPTI) is developing a range of technologies, which modulate the human microbiome to prevent and manage human disease. A global market of strategic interest to pharmaceutical, food, health and wellbeing companies, the human microbiome is forecast to become one of the world’s fastest growth areas.
OptiBiotix identifies and develops microbial strains, compounds and formulations for use in food ingredients, supplements and active compounds that can impact on human physiology, deriving potential health benefits.
With an established pipeline of microbiome modulators, the OptiBiotix team works in the prevention and management of chronic lifestyle diseases including obesity, hypercholesterolemia and lipid profiles, and diabetes.
+ Click for info
Qudini
- Click to close
Qudini
Founded in 2012, Qudini is a B2B software company that provides customer experience SaaS solutions to organisations in retail, hospitality, the public sector and healthcare.
Qudini provides a software solution for appointment bookings, queue management, event management and task management – enabling businesses to improve shop floor operations by managing staff activity, breaks and performance, and by assigning tasks at store or head office level.
Qudini is aiming to revolutionise digital queue and appointment management. It achieves this through deployment of its data-centric, cloud-based (Amazon Web Services), cross-platform service, which improves a business’ ability to manage the flow of customers awaiting service, using algorithms to provide accurate, live data, such as estimated wait times. Wait times are relayed to the customer typically via an SMS/text sent from the Qudini platform. Through integration with various software platforms and compatible with wide variety of hardware, Qudini enables detailed analytics focused on customer trends, and provides a unique insight into areas such as customer footfall, peak demand times, and wait times.
+ Click for info
SkinBioTherapeutics Plc
- Click to close
SkinBioTherapeutics Plc
SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Cath O’Neill and Professor Andrew McBain.
SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.
The aim of the Company is to develop its SkinBiotix® technology into commercially successful products supported by a strong scientific evidence base. SkinBioTherapeutics’ commercial strategy is to engage health and wellbeing and/or pharmaceutical companies in early dialogue to build up relationships and maintain communication on technical progress until one or more commercial deals can be secured.